Twenty years after opening, the H. Lee Moffitt Cancer Center &Research Institute is submitting its second competitive renewal application for its Cancer Center Support Grant for grant years 10 through 14. The Center's mission remains solely focused on """"""""contributing to the prevention and cure of cancer."""""""" The Moffitt Cancer Center, a freestanding, not-for-profit corporation located on the University of South Florida campus in Tampa, Florida, includes a research institute coupled with a 162-bed inpatient facility, an active outpatient clinic with more than 200,000 patient visits per year, a high-risk screening and prevention center, a dedicated Clinical Research Unit for early phase studies, an affiliate network of Florida hospitals and oncology practices and a wide array of outreach and educational activities. The Cancer Center has five scientific programs, all with a translational focus;14 shared resources (five newly proposed), and a research infrastructure that supports innovative, translational research and enhances interactions among basic scientists, population-based scientists and clinical investigators. Research programs include Molecular Oncology &Drug Discovery, Immunology, Experimental Therapeutics, Risk Assessment, Detection &Intervention, and Health Outcomes &Behavior. Shared resources include Flow Cytometry, Molecular Biology, Microarray, Proteomics, High Throughput Screening &Chemistry, Mouse Models, Analytic Microscopy, Tissue, Cell Therapies, Survey Methods, Informatics, Biostatistics, Clinical Research Support Services and the Clinical Trials Laboratory Core. The Protocol Review &Monitoring System includes two Scientific Review Committees and a separate Protocol Monitoring Committee. Protocol specific support for a large-volume early phase clinical trial portfolio is also requested. During the period since designation as an NCI Comprehensive Cancer Center and the current CCSG submission (2001-2006), the Center has more than doubled its peer reviewed funding and increased NCI funding from $10.6 million to $29 million total dollars;increased accrual to phase I investigator-authored clinical trials from 130 to 534 annually and enrollment on all trials to more than 6,000;opened the Stabile Research Building to nearly double available research space;and created a network of 16 affiliate hospitals and 380 physicians throughout Florida. The Center's 135 members collaborate extensively with 25% of total publications being inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA076292-11S1
Application #
7763517
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ogunbiyi, Peter
Project Start
1998-02-18
Project End
2012-01-31
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
11
Fiscal Year
2009
Total Cost
$126,002
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Karolak, Aleksandra; Markov, Dmitry A; McCawley, Lisa J et al. (2018) Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues. J R Soc Interface 15:
Liu, Ying; Wang, Hua; Li, Qian et al. (2018) Radiologic Features of Small Pulmonary Nodules and Lung Cancer Risk in the National Lung Screening Trial: A Nested Case-Control Study. Radiology 286:298-306
Padron, Eric; Ball, Markus C; Teer, Jamie K et al. (2018) Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood 131:2402-2405
Verduzco, Daniel; Kuenzi, Brent M; Kinose, Fumi et al. (2018) Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Mol Cancer Ther 17:73-83
Lee, Morgan S; Tyson, Dinorah Martinez; Gonzalez, Brian D et al. (2018) Anxiety and depression in Spanish-speaking Latina cancer patients prior to starting chemotherapy. Psychooncology 27:333-338
Correa, John B; Brandon, Karen O; Meltzer, Lauren R et al. (2018) Electronic cigarette use among patients with cancer: Reasons for use, beliefs, and patient-provider communication. Psychooncology 27:1757-1764
Divakaran, Anand; Talluri, Siva K; Ayoub, Alex M et al. (2018) Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem 61:9316-9334
de Mingo Pulido, Álvaro; Gardner, Alycia; Hiebler, Shandi et al. (2018) TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell 33:60-74.e6
Li, Gongbo; Boucher, Justin C; Kotani, Hiroshi et al. (2018) 4-1BB enhancement of CAR T function requires NF-?B and TRAFs. JCI Insight 3:
McIntyre, Jessica; Jiménez, Julio; Rivera, Yonaira M et al. (2018) Comparison of Health Communication Channels for Reaching Hispanics About Biobanking: a Pilot Trial. J Cancer Educ 33:833-841

Showing the most recent 10 out of 1254 publications